CTAG1B and cervical cancer: To investigate the in vivo efficacy of the combined treatment of OVV-01 and NY-ESO-1 TCR-T cells, we established a Caski (HLA-A2+/NY-ESO-1-) human cervical cancer cell line NOG mouse subcutaneous xenograft model.